A small business from Germany active in the field of biotechnology is looking for partners for the Call "Comparing the effectiveness of existing healthcare interventions in the adult population", SC1-PM-10-2017 in Horizon 2020. The company would like to head the consortium.
The project will be called „Effectiveness of existing healthcare interventions in rheumatic arthritis therapy with therapeutic antibodies”. The aim of the project is the systematic analysis of rheumatic arthritis therapy based on therapeutic antibodies. Therefore, the project will address three dimensions of improving the therapy of rheumatic arthitis.
First, the project will analyse comprehensive diagnostic data to elucidate the drug/target interaction.
Second, the project should develop patients-centered therapeutic drug monitoring (TDM) for a personalised drug dose.
And third, the project will analyse the cost effectiveness of the "anti TNF alpha" therapy in rheumatic arthritis patients. This novel therapy coming from cancer treatment aims at curing rhematic arthritis by modifying the inflammatory disease process in the bone affected.
The company has expertise in immunochemistry and will contribute a technology to monitor a free drug, a free antigen and a drug/antigen complex in rheumatic arthritis patient's sera during therapy.
The company is looking for project partners from Horizon 2020 partner countries with expertise in rheumatic arthitis research and product innovation.
More specifically they look for:
- a small-or-medium-sized business active in rheumatic arthritis diagnostics, biomarker evaluation, proteomics, metabolomics and genetics,
- clinics, universities and research institutes involved in rheumatic arthritis treatment, research and e-health projects,
- medical study design experts and large scale data analyst,
- health economics and public health experts.
The framework conditions of the call are those of a Research & Innovation Action. The direct costs a reimbursed 100%, whereas 20% of the indirect costs are reimbrused. The partners of the project need to be a legal entity established in one of the participating countries of the EU. The budget of the application will be between 4 and 5 Mio EUR.
The deadline for EOIs is 30 June 2016. The deadline for the first stage of applications is 4 October 2016. The deadline for the second stage is 11 April 2017. The project duration will be maximum 48 months.
